AML VACCIN news
On February 28 2020 Jean-Eric Paquet (Director-General of the Research and Innovation department) wrote the following on Twitter: ”Rare diseases are a priority area of research funding for the EU. This is why we will continue to ...
In the latest edition of MedNous, Erik Manting, CEO of DCprime B.V. elaborates on the role of relapse vaccines in Acute myeloid leukemia. Read this article by clicking on the following link: Article_RelapseVaccines_ErikManting Nov-Dec ...
On 13 June 2019 the Third AML-VACCiN Consortium Meeting was held in Amsterdam, The Netherlands. During this meeting progress on the overall objectives, financial status and encountered hurdles were discussed. Good progress was reported ...
In collaboration with the University of Bergen, Norway, DCprime has established a preclinical mouse model to study DCP-001 vaccinations in monotherapy and in combination therapy settings. The collaboration is supported by the Horizon ...
At the 2019 CIMT Annual Meeting, preclinical study data have been presented, as DCprime was able to demonstrate that human antigen presenting cells (APCs) efficiently process DCP-001 through phagocytosis. These in vitro data suggest ...
On 29 January 2019 DCprime has received approval from the Norwegian Medicines Agency NoMa for the ADVANCE-II / DCOne-002 clinical study entitled ‘An international, multicenter, open-label study to evaluate the efficacy and safety of ...
DCprime, participant of the EU sponsored Horizon2020 AML-VACCiN project, has announced that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete ...
On 04 September 2018 DCprime has received approval from the German Paul-Ehrlich-Institute for the ADVANCE-II / DCOne-002 clinical study entitled ‘An international, multicenter, open-label study to evaluate the efficacy and safety of ...
DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy. This study was the starting point for the EU-funded AML-VACCiN project. The phase I ...
In August 2017, the AML-VACCiN consortium delivered its scientific report over the first 18 months. We have made major progress for all the objectives that we set at the start of this ambitious project. In preparation of the clinical ...
